Multicenter research of comparison between prasugrel and clopidogrel in ischemic heart disease undergoing PCI
Not Applicable
- Conditions
- Ischemic heart disease
- Registration Number
- JPRN-UMIN000029481
- Lead Sponsor
- Chiba University Graduate school of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1500
Inclusion Criteria
Not provided
Exclusion Criteria
Prescribed P2Y12 inhibitors before first PCI more than a month ago Switching P2Y12 inhibitors within 2weeks without comprehensible reasons Self-interruption of P2Y12 inhibitors Follow-up periods within 2 weeks Not documented doses of P2Y12 inhibitors
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Major adverse cardiovascular events (MACE) were defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal ischemic stroke. Adverse events were defined as a composite of bleeding, hepatopathy, leukopenia, thrombopenia, exanthema, and MACE.
- Secondary Outcome Measures
Name Time Method